Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.33 |
| ▸ | GCGR | P47871 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3702569 | 0.87 | BACE1 (0.33) | — | |
| SCHEMBL27935758 | 0.85 | KCNH2 (0.43) | KCNH2SPHK1S1PR4S1PR1 | |
| SCHEMBL28226762 | 0.85 | KCNH2 (0.43) | KCNH2SPHK1S1PR4S1PR1S1PR5 | |
| SCHEMBL1436379 | 0.85 | KCNH2 (0.43) | KCNH2SPHK1S1PR4S1PR1S1PR5 | |
| SCHEMBL3702219 | 0.79 | ESR1 (0.30) | — | |
| SCHEMBL10754466 | 0.78 | HTR1D (0.35) | TDP1 | |
| SCHEMBL7701413 | 0.76 | KCNH2 (0.47) | KCNH2PDPK1 | |
| SCHEMBL1063754 | 0.76 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL8675141 | 0.75 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL9817100 | 0.74 | KCNH2 (0.50) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | KCNH2 4052/4885PDPK1 2283/4885SPHK1 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.